Equillium to Present at the Jefferies Global Healthcare Conference
29 Maggio 2024 - 2:00PM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders, today announced that it will
present at the Jefferies Global Healthcare Conference taking place
at the Marriott Marquis in New York, NY, June 4 – 6, 2024.
Management will provide an overview of the company’s clinical
programs – including EQ101 for the treatment for alopecia areata
with data expected before the end of June 2024 – the company’s
partnership with Ono Pharmaceutical, and 2024 milestones.
Management will also be available for one-on-one meetings during
the conference.
Conference:
Jefferies Global Healthcare Conference
Location:
Marriott Marquis, Track 8 - Gramercy, 7th
Floor
Date:
Wednesday, June 5
Time:
7:30 am Pacific Time | 10:30 am Eastern
Time
Webcast access will be available on the “Events &
Presentations” page under the Investor Relations tab on the
Company’s website at
https://www.equilliumbio.com/investors/events-and-presentations/default.aspx.
An archived replay of the conference will be available for 90
days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets and product
platform targeting immuno-inflammatory pathways. EQ101: a selective
tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15;
currently under evaluation in a Phase 2 proof-of-concept clinical
study of patients with alopecia areata being conducted in Australia
and New Zealand by Equillium’s Australian subsidiary as the trial
sponsor. EQ302: an orally delivered, selective bi-specific cytokine
inhibitor targeting IL-15 and IL-21; currently in pre-clinical
development. The multi-cytokine platform: generates rationally
designed composite peptides that selectively block key cytokines at
the shared receptor level targeting pathogenic cytokine
redundancies and synergies while preserving non-pathogenic
signaling. Itolizumab: a monoclonal antibody that targets the
CD6-ALCAM signaling pathway which plays a central role in the
modulation of effector T cells; currently under evaluation in a
Phase 3 clinical study of patients with acute graft-versus-host
disease (aGVHD) and recently completed a Phase 1b clinical study of
patients with lupus/lupus nephritis. Equillium acquired rights to
itolizumab through an exclusive partnership with Biocon Limited and
has entered a strategic partnership with Ono Pharmaceutical Co.,
Ltd., for the development and commercialization of itolizumab under
an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; and whether the results
from clinical studies will validate and support the safety and
efficacy of Equillium’s product candidates. These and other risks
and uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov and on Equillium’s website
under the heading “Investors.” Investors should take such risks
into account and should not rely on forward-looking statements when
making investment decisions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529082041/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Dic 2023 a Dic 2024